Over two million people in Europe live with an inflammatory bowel disease (IBD). Besides, the number of patients is increasing and it’s become one of the most common immune-mediated diseases in young adults. Among the IBDs, Crohn’s disease and ulcerative colitis, are the most common. The current treatments include drugs and biological therapy. But, their efficacy is low and both … Read More
INSERM meets IDIBAPS
Sharing knowledge and experiences is key for a successful project! And that’s why our partners from INSERM and IDIBAPS are working together in Barcelona these days. For a few weeks both teams will join forces and work in close collaboration to perform biodistribution and efficacy assays. Keep up the good work!
Success in Barcelona: 4th General Assembly and first review meeting
The months keep passing by and at New Deal we continue striving to develop a new treatment against IBD. Our partner institutions are working in parallel in countries across Europe and thus, regularly putting all this efforts in common face to face is key to keep the project on track. With this idea in mind, we gathered earlier this month … Read More
NEW DEAL was rewarded at Mayoly’s Forum
The Mayoly Management Forum took place from the 5th to the 8th of February, in Valence. The event gathered all the managers from Mayoly and at this occasion the New Deal project was presented. A new nanotherapy research for inflammatory bowel diseases The goal of the project NEW DEAL is to design and validate a new targeted therapy against inflammatory bowel diseases (IBDs). This … Read More
NEW DEAL at European Technology Plateform on Nanomedicine 2017
At the occasion of the 12th annual event of the European Technology Platform on Nanomedicine in Malaga, Spain, Dr Fabrice Navarro from CEA-LETI was invited to present New Deal as an innovative project in nanomedicine. Daniel Perez from Nanoimmunotech, another member of the consortium, was also present during this event. ETPN is the occasion to discuss current trends, to meet and … Read More
New EU project develops a highly selective and local therapy for Inflammatory Bowel Diseases
The innovations introduced by NEW DEAL strengthen the leadership of Europe in the field of advanced therapies and in particular, in nanotherapies. An alternative therapy for inflamatory bowel diseases (IBDs) The goal of the new European project NEW DEAL is to design and validate a new targeted therapy against inflammatory bowel diseases (IBDs). This therapy is aimed at treating patients … Read More